Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-04-16

FDA Approved: DYMISTA — Supplemental Application (Viatris Specialty LLC)

View source ↗

Summary

FDA approved a supplemental application for DYMISTA (azelastine hydrochloride and fluticasone propionate) submitted by Viatris Specialty LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DYMISTA (azelastine hydrochloride and fluticasone propionate)

Snippet

SUPPL AP for DYMISTA (AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE)